Advances in molecular technologies have led to the discovery of several novel human polyomaviruses (HPyVs), including human polyomavirus-7 (HPyV-7). Although low levels of HPyV-7 are shed from apparently normal skin, recent reports have described clinically significant cutaneous infection in immunocompromised patients that manifests as generalized pruritic plaques. The pruritus can be severe, and treatment options have not been described. Herein we report HPyV-7 cutaneous infection in a heart transplant patient who experienced temporary improvement with intravenous cidofovir, and complete remission with acitretin. We report a case of HPyV-7 cutaneous infection demonstrating a good response to treatment.
K E Y W O R D S
biopsy, clinical research/practice, complication: infectious, dermatology, heart (allograft) function/dysfunction, immunosuppressant -mechanistic target of rapamycin (mTOR), infection and infectious agents -viral: BK/JC/polyoma, infectious disease characterized by unique histopathology findings that have been described as resembling peacock plumage with prominent eosinophilic viral inclusion found in the epidermis. 10, 11 A very similar clinical and histological presentation has also been described in association with
HPyV-6 infection. 12 Here we report a case of HPyV-7 infection resulting in a pruritic eruption in an immunosuppressed patient. This patient's unpublished clinical presentation and histology were previously presented in poster format. 13 This is the first report of such an eruption treated successfully with cidofovir and acitretin. This eruption may be underreported in the literature, as this virus has only recently been discovered.
| CASE REPORT
A 48-year-old Caucasian man with a history of 2 cardiac transplantations presented to our dermatology clinic with complaints of a diffuse pruritic eruption. The patient had a history of ischemic heart disease necessitating cardiac transplantation 13 years before presentation, and his transplant course was complicated by graft rejection. The patient's second cardiac transplant, which was 5 years before presen- The patient's pruritus was sufficiently severe that reduction of his immunosuppression was considered; however, this was not a viable option given his ongoing allograft vasculopathy. He was briefly transitioned from sirolimus to mycophenolate mofetil (MMF) in the perioperative period for a cholecystectomy; however, his pruritus did not improve, and he was transitioned back to sirolimus after 6 weeks. 
| DISCUSSION
Immunocompromised patients are at risk for numerous oppor- HPyV-7 and HPyV-6 are both members of the normal human biome and are present in roughly 11% and 30%, respectively, of asymptomatic normal skin swabs. 7, 17 Given the relative high prevalence and chronic low level shedding of complete virons from normal skin, horizontal transmission likely occurs from skin contact for both viruses. 18 Although neither HPyV-6 nor HPyV-7 is associated with cutaneous malignancies or common inflammatory skin conditions, both viruses are found more often on the normal skin of patients with HIV relative to health controls. 17, 19 In addition to cutaneous involvement, Herein we report the fourth published case of clinically relevant HPyV-7 cutaneous infection in an immunosuppressed patient (Table 1) .
Two prior cases appeared in lung transplant recipients, both of whom had similar severely pruritic diffuse plaques associated with distinctive morphology, which was akin to what was seen in our patient. 10 Histology from these cases was distinctive and was described as resembling peacock plumage with eosinophilic keratinocytes with viral inclusions at varying levels in the epidermis. Viral sequencing from these cases revealed mutations in the HPyV-7-noncoding region, which the authors suggest may impart increased virulence in immunodeficient patients. Treatment was not described in this case series.
A similar case of HPyV-7 infection was also reported in a patient with AIDS with manifestations that included diffuse pruritic scaly plaques. 11 Histology in this case showed tiers of parakeratosis overlying columns of dyskeratotic keratinocytes. PCR testing in this patient was positive not only for HPyV-7 but also several other HPyVs, and she was ultimately was given a diagnosis of a variant of epidermodysplasia verruciformis. The patient's condition failed to improve with topical triamcinolone 0.1% cream, emollients, cetirizine, and narrowband ultraviolet B; and she was noncompliant with cimetidine 400 mg 3 times daily orally, AmLactin 12% topical cream twice daily, and hydroxyzine.
Of interest, strikingly similar pruritic gray-brown plaques have also been reportedly associated with HPyV-6 infection in 2 patients.
12,23
HPyV-6 previously had not been linked with cutaneous disease. One of these patients was iatrogenically immunosuppressed following a kidney and pancreas transplantation, whereas the other patient did not carry any known diagnosis of immunodeficiency but was speculated to have an uncharacterized acquired immunodeficiency based on a history of frequent severe infections necessitating hospitalization. Histology from these cases demonstrate findings that are similar and distinctive to the prior cases and include papillomatosis, dyskeratotic cells in the superficial epidermis, and columns of dyskeratosis in the stratum corneum.
Although this histologic pattern is distinctive, it is not pathognomonic for polyomavirus infection and has been identified in specimens that are negative for HPyV-6 and HPyV-7 by PCR. 12 It is interesting to note that the eruption spontaneously resolved after over 1 year for the patient with the unknown immunodeficiency diagnosis. This patient continued to shed HPyV-6 even after resolution of the eruption.
HPyV-associated hyperproliferative keratinopathy plus/minus pruritus is a term that has been used to describe these related conditions associated with HPyV-6 and HPyV-7. This term is valuable as it identifies expression of HPyV large T-antigen as the proliferative driver. The clinical response seen in our patient after cidofovir treatment supports the role of the virus driving this clinical condition.
All cases have had strikingly similar presentations and histology, suggesting that these cases may represent a syndrome. All patients complained of severe pruritus and had thin, slightly scaly or lichenified gray-brown to light pink papules and plaques that were most pro- 
| CONCLUSION
The clinical and histological findings associated with this condition are both striking and unique. Pruritus, which is a common complaint reported by SOTR and is often attributed to medication effects, can be related to numerous infectious causes. Because HPyV-7 is a newly reported virus, it is possible that with increased awareness of this distinct presentation and histologic findings that many more cases will be discovered. Further research is needed to validate the efficacy of acitretin, and to better elucidate the relationship of mTORis and HPyV-7 replication. This case offers both diagnostic and therapeutic tools for those caring for patients with immunodeficiencies, and this infection should be considered in the correct clinical setting.
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